Catalyst staves off Firdapse competition from Teva for a decade
Catalyst Pharmaceuticals' controversial $375,000 rare autoimmune disease drug now won't face generic competition from Teva until Feb. 25, 2035, thanks to a patent settlement announced by the two...
View ArticleBayer says elinzanetant quelled hot flashes in women undergoing cancer treatment
As Bayer awaits an FDA decision on its non-hormonal treatment for hot flashes caused by menopause, the company is unveiling new results in a slightly different patient population: women whose hot...
View ArticleIGM Biosciences’ autoimmune pivot lasts three months after interim data...
About three months ago, IGM Biosciences announced plans to stay afloat by focusing its resources on a clinical-stage autoimmune asset. Now the company is shelving the drug, laying off most of its...
View ArticleShoreline cuts staff as its partnership with Gilead's Kite is now in flux
Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project that's working with Gilead's Kite unit. Shoreline CEO Kleanthis Xanthopoulos...
View ArticleIntellia to cut workforce by 27%, targets 2027 commercial launch
Intellia Therapeutics is the latest CRISPR company resorting to layoffs as investors increasingly turn away from gene editing. The Cambridge, MA-based company announced Thursday that it would reduce...
View ArticleWith $120M, GSK-allied Ouro Medicines throws its hat into burgeoning TCE ring
T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting medicines, known simply as TCEs, are being adopted from the oncology field as a...
View ArticleMarea reports early Phase 2 data for cholesterol-lowering drug it licensed...
Marea Therapeutics on Friday posted some encouraging results with its lead program, a triglyceride-lowering medicine for cardiovascular disease, that could give an indication of whether the investors...
View ArticleRepare pauses late-stage plans, reshuffles pipeline in effort to cut costs
Repare Therapeutics is slamming the brakes on its gynecologic cancer assets and prioritizing earlier-stage candidates as part of a series of changes designed to stretch its cash reserves. The biotech is
View ArticleLilly ventures into pulmonary fibrosis with startup Mediar
Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — one of the five large pharmas backing Mediar – will pay $99 million in...
View ArticleJohn Maraganore turns to ex-Alnylam colleague to lead his latest RNAi bet;...
→ City Therapeutics broke cover in October with a $135 million Series A and the opportunity for executive chairman John Maraganore to run it back with RNAi-based therapies. This week, the company ...
View ArticleAnother biotech scoops up asset from China-based Keymed and nabs $180M
Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors propping up new companies to further develop assets discovered or initially...
View ArticleCDER Director Patrizia Cavazzoni to step down
Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, will step down, the agency confirmed Friday. An email was sent to employees announcing the departure. "Leaving CDER...
View ArticleFour biotechs emerge with $800M and in-licensed assets on Friday
Four new biotechs launched Friday with megarounds and in-licensed treatment candidates, giving the industry an $800 million boost ahead of the year's biggest dealmaking event in San Francisco. Three of...
View ArticleCity Therapeutics, Bausch + Lomb partner on preclinical RNAi eye drug
With its new CEO installed this week, City Therapeutics is aiming to capitalize on the momentum in signing a new deal. The startup is partnering with Bausch + Lomb on an experimental ...
View ArticleStemson Therapeutics shutters; Insilico teams up again with Menarini
Plus, news about Crinetics, Compass Pathways, Amylyx Pharmaceuticals, Mersana Therapeutics, Guggenheim Partners, Sciwind Biosciences, 4D Molecular Therapeutics, Barinthus Bio, Y-mAbs Therapeutics and...
View ArticleEndpoints at JPM 2025: China, Trump 2.0, markets and more
When we started putting together this year’s JPM agenda, we had three major focus areas: The transition to Trump 2.0; the on-again, off-again market recovery, and the evolving US-China dynamic. These...
View ArticleModerna's former top scientist Moore has a new mRNA startup
Melissa Moore helped usher in the first mRNA medicines, but the former Moderna executive thinks there’s still a lot of room for improvement. The rapid success of the first mRNA vaccines during the...
View ArticleAbbVie writes off $3.5B on Cerevel drug after Phase 2 failures
AbbVie is taking a major loss in the wake of its Cerevel buyout. AbbVie said it will write off $3.5 billion following two mid-stage failures for emraclidine, the experimental schizophrenia drug that...
View ArticleDyne details pivotal plans for myotonic dystrophy RNA drug, though data blip...
Dyne Therapeutics touted an early-stage study of its RNA treatment for myotonic dystrophy type 1 and has selected the dose it plans to move forward into pivotal studies. However, the company’s shares...
View ArticleLilly finances new $500M biotech fund managed by a16z
Eli Lilly is expanding its private financing ambitions, partnering with venture capital firm Andreessen Horowitz on a new $500 million biotech fund. The pharma company is providing all the capital for...
View Article